Contrasting of Ocular Therapeutix Inc. (OCUL) and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI)

We will be comparing the differences between Ocular Therapeutix Inc. (NASDAQ:OCUL) and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) as far as institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ocular Therapeutix Inc. 1.97M 74.07 55.68M -1.59 0.00
Spectrum Pharmaceuticals Inc. 108.50M 10.79 99.35M -0.60 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Ocular Therapeutix Inc. and Spectrum Pharmaceuticals Inc.

Profitability

Table 2 provides us the return on assets, return on equity and net margins of both companies.

Net Margins Return on Equity Return on Assets
Ocular Therapeutix Inc. -2,826.40% -133.7% -81.6%
Spectrum Pharmaceuticals Inc. -91.57% -30.6% -22.1%

Risk & Volatility

A 1.61 beta means Ocular Therapeutix Inc.’s volatility is 61.00% more than S&P 500’s volatility. From a competition point of view, Spectrum Pharmaceuticals Inc. has a 2.28 beta which is 128.00% more volatile compared to S&P 500.

Liquidity

4.3 and 4.3 are the respective Current Ratio and a Quick Ratio of Ocular Therapeutix Inc. Its rival Spectrum Pharmaceuticals Inc.’s Current and Quick Ratios are 2.6 and 2.6 respectively. Ocular Therapeutix Inc. has a better chance of clearing its pay short and long-term debts than Spectrum Pharmaceuticals Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for Ocular Therapeutix Inc. and Spectrum Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ocular Therapeutix Inc. 0 0 0 0.00
Spectrum Pharmaceuticals Inc. 0 0 2 3.00

Competitively the consensus price target of Spectrum Pharmaceuticals Inc. is $24, which is potential 117.19% upside.

Insider & Institutional Ownership

Ocular Therapeutix Inc. and Spectrum Pharmaceuticals Inc. has shares held by institutional investors as follows: 53.2% and 84%. About 0.2% of Ocular Therapeutix Inc.’s share are held by insiders. Insiders Comparatively, held 0.6% of Spectrum Pharmaceuticals Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ocular Therapeutix Inc. -15.92% 3.51% -18.13% -22.76% 39.65% 25.84%
Spectrum Pharmaceuticals Inc. -12.03% -3.93% -38.1% -36.05% -33.05% -32.88%

For the past year Ocular Therapeutix Inc. has 25.84% stronger performance while Spectrum Pharmaceuticals Inc. has -32.88% weaker performance.

Summary

Spectrum Pharmaceuticals Inc. beats Ocular Therapeutix Inc. on 7 of the 11 factors.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology. Its product pipeline candidates utilize its platform to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release one-time or several-month dosage forms. The companyÂ’s lead product candidate, DEXTENZA (dexamethasone insert) 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. It is also developing OTX-TP (travoprost insert), which is in Phase 3 clinical development for glaucoma and ocular hypertension. In addition, the company is evaluating injectable drug delivery depots for back-of-the-eye diseases. Further, its commercial product includes the ReSure Sealant, which has been approved by the Food and Drug Administration (FDA) for ophthalmic use. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-HodgkinÂ’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.